Positive Results Reported from Phase 3 CABINET Trial

Positive results are reported from the Phase 3 CABINET trial evaluating the drug cabozantinib in advanced neuroendocrine tumors. Interim data shows significant improvement in progression-free survival for advanced NETs that progressed on prior systemic therapies.

No new adverse effects were found in the trial beyond cabozantinib’s known safety profile. This drug, while FDA-approved for other diseases, has not yet been FDA-approved for NETs. The findings from this trial will be presented at an upcoming medical meeting and further discussed with the FDA. Read the press release here.

In 2018, NETRF funded a pilot project to Dr. Jennifer Chan, the study chair for the CABINET trial, to evaluate data and patient samples from a Phase 2 clinical trial of cabozantinib to look for biomarkers that could predict response.

NETRF is pleased to see progress in the pipeline for new treatments for NETs, particularly those that have progressed on prior treatment.

“Patients with progressive neuroendocrine tumors have limited treatment options. At present, after progression on previous therapies, the treatment path is unclear, underscoring the need for additional options for this disease that is rising in incidence,” said Jennifer Chan, MD, MPH, study chair for the CABINET trial and Clinical Director of the Gastrointestinal Cancer Center and Director of the Program in Carcinoid and Neuroendocrine Tumors at Dana-Farber Cancer Institute. “These promising findings from the CABINET trial, in which cabozantinib showed an efficacy benefit for patients with pancreatic and extra-pancreatic neuroendocrine tumors, are welcome news and show the potential for cabozantinib to address important unmet needs for this community.”